Topiramate use in pediatric patients

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology
• Epileptology

Background:

• Topiramate (TPM) is an established antiepileptic medication for adult partial onset seizures.
• Pediatric efficacy for TPM as adjunctive therapy required further investigation in specific epilepsy syndromes.

Purpose of the Study:

• To evaluate the efficacy and tolerability of topiramate as adjunctive therapy in children.
• To assess TPM's effectiveness in childhood epileptic encephalopathy (Lennox-Gastaut syndrome) and refractory partial onset seizures.

Main Methods:

• Two randomized, double-blind, placebo-controlled trials were conducted in pediatric populations.
• Efficacy was assessed by seizure reduction, and dose-response was evaluated across double-blind and open-label phases.
• Tolerability and side effects were monitored, with specific dosing recommendations explored.

Main Results:

• Topiramate significantly reduced drop attacks in Lennox-Gastaut syndrome patients.
• TPM significantly decreased partial onset seizures in children with refractory epilepsy.
• Efficacy improved with dose escalation, suggesting a minimum effective dose of 6 mg/kg/day.

Conclusions:

• Topiramate is an effective adjunctive therapy for specific pediatric epilepsy syndromes.
• A 'start low, go slow' titration strategy (0.5-1 mg/kg/day initially) enhances tolerability.
• Topiramate represents a valuable addition to the pediatric antiepileptic drug armamentarium.